These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 16278010)
21. Clinical picture of women with early stage ovarian cancer. Eltabbakh GH; Yadav PR; Morgan A Gynecol Oncol; 1999 Dec; 75(3):476-9. PubMed ID: 10600311 [TBL] [Abstract][Full Text] [Related]
22. Factors predictive of elevated serum CA125 levels in patients with epithelial ovarian cancer. Bouanène H; Harrabi I; Ferchichi S; Ben Limem H; Miled A Bull Cancer; 2007 Jul; 94(7):E18-22. PubMed ID: 17723943 [TBL] [Abstract][Full Text] [Related]
23. [Immunohistochemical flow chart to differentiate between primary adenocarcinoma and the most frequent extragynecological metastases in the ovary]. Pires Y; Andrade L; Cuello M; Chuaqui R Rev Med Chil; 2002 Nov; 130(11):1232-40. PubMed ID: 12587505 [TBL] [Abstract][Full Text] [Related]
24. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447 [TBL] [Abstract][Full Text] [Related]
25. Metastatic mucinous adenocarcinoma of the ovary is characterized by advanced patient age, small tumor size, and elevated serum CA125. Maeda-Taniguchi M; Ueda Y; Miyake T; Miyatake T; Kimura T; Yoshino K; Fujita M; Wakasa T; Ohashi H; Morii E; Enomoto T; Kimura T Gynecol Obstet Invest; 2011; 72(3):196-202. PubMed ID: 21893929 [TBL] [Abstract][Full Text] [Related]
26. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Brakora KA; Lee H; Yusuf R; Sullivan L; Harris A; Colella T; Seiden MV Gynecol Oncol; 2004 May; 93(2):361-5. PubMed ID: 15099946 [TBL] [Abstract][Full Text] [Related]
27. Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer. Skírnisdóttir I; Garmo H; Holmberg L Gynecol Oncol; 2007 Apr; 105(1):166-71. PubMed ID: 17184826 [TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction. Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967 [TBL] [Abstract][Full Text] [Related]
29. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D J BUON; 2007; 12(1):99-104. PubMed ID: 17436409 [TBL] [Abstract][Full Text] [Related]
30. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282 [TBL] [Abstract][Full Text] [Related]
31. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323 [TBL] [Abstract][Full Text] [Related]
32. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916 [TBL] [Abstract][Full Text] [Related]
33. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584 [TBL] [Abstract][Full Text] [Related]
34. Primary ovarian mucinous tumors with signet ring cells: report of 3 cases with discussion of so-called primary Krukenberg tumor. McCluggage WG; Young RH Am J Surg Pathol; 2008 Sep; 32(9):1373-9. PubMed ID: 18670351 [TBL] [Abstract][Full Text] [Related]
35. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI. Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039 [TBL] [Abstract][Full Text] [Related]
36. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148 [TBL] [Abstract][Full Text] [Related]
37. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030 [TBL] [Abstract][Full Text] [Related]
38. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420 [TBL] [Abstract][Full Text] [Related]
39. Prognostic value of Ca 125 levels during primary therapy. Markmann S; Gerber B; Briese V Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781 [TBL] [Abstract][Full Text] [Related]
40. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]